Thiazolidinediones News and Research

RSS
Thiazolidinediones are adjunctive therapies for diabetes mellitus (type 2) and related diseases.
Study describes pharmacological action of TZDs directly on pancreas

Study describes pharmacological action of TZDs directly on pancreas

FDA approves Takeda’s NESINA, OSENI and KAZANO for treatment of type 2 diabetes

FDA approves Takeda’s NESINA, OSENI and KAZANO for treatment of type 2 diabetes

Common diabetes treatment may cause bladder cancer

Common diabetes treatment may cause bladder cancer

Abscisic acid has anti-inflammatory effects in the lungs and gut

Abscisic acid has anti-inflammatory effects in the lungs and gut

Diabetes drug raises bladder cancer risk

Diabetes drug raises bladder cancer risk

Pioglitazone may raise bladder cancer risk

Pioglitazone may raise bladder cancer risk

Pioglitazone may raise bladder cancer risk

Pioglitazone may raise bladder cancer risk

Thiazolidinedione drugs linked with increased risk of DME in patients with Type 2 diabetes

Thiazolidinedione drugs linked with increased risk of DME in patients with Type 2 diabetes

Researchers identify new mitochondrial protein complex linked with type 2 diabetes

Researchers identify new mitochondrial protein complex linked with type 2 diabetes

Increased risk of bladder cancer linked to diabetes drug

Increased risk of bladder cancer linked to diabetes drug

NCoR deficiency may pump up muscles and prevent diabetes

NCoR deficiency may pump up muscles and prevent diabetes

Byetta combination with insulin glargine gets FDA nod in type 2 diabetes

Byetta combination with insulin glargine gets FDA nod in type 2 diabetes

Researchers create powerful anti-diabetic prototype drugs with lesser side effects

Researchers create powerful anti-diabetic prototype drugs with lesser side effects

Takeda resubmits alogliptin and fixed-dose combination therapy NDA to FDA

Takeda resubmits alogliptin and fixed-dose combination therapy NDA to FDA

New biological insights into fat tissue

New biological insights into fat tissue

Key regulator of fat cell development may provide a target for obesity and diabetes drugs

Key regulator of fat cell development may provide a target for obesity and diabetes drugs

TZDs might serve as new agents for addiction treatment

TZDs might serve as new agents for addiction treatment

Type 2 diabetes drug less likely to cause weight gain, raise cholesterol levels

Type 2 diabetes drug less likely to cause weight gain, raise cholesterol levels

FDA accepts Merck's JANUMET extended-release formulation NDA for type 2 diabetes

FDA accepts Merck's JANUMET extended-release formulation NDA for type 2 diabetes

VYTORIN reduces major vascular events in patients with chronic kidney disease

VYTORIN reduces major vascular events in patients with chronic kidney disease

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.